SCHEMBL18166015

SCHEMBL18166015

COc1c(Cl)nc(S(C)(=O)=O)nc1Nc1cc(C)[nH]n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
PLK4 O00444 2/20 0.43
PAK4 O96013 2/20 0.43
AURKA O14965 12/20 0.40
AURKB Q96GD4 8/20 0.39
GSK3B P49841 5/20 0.38
PIK3C3 Q8NEB9 1/20 0.38
SYK P43405 1/20 0.38
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
JAK2 O60674 3/20 0.37
JAK3 P52333 2/20 0.37
SRC P12931 1/20 0.37
DAPK3 O43293 1/20 0.37
ABL1 P00519 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18165979 0.79 AURKA (0.44) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL12102888 0.78 GSK3B (0.50) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL25260418 0.73 BRAF (0.39) MEN1HTTKMT2AHSD17B10LMNA
SCHEMBL30448315 0.73 BRAF (0.39) MEN1HTTKMT2AHSD17B10LMNA
SCHEMBL25619858 0.72 SMN1; SMN2 (0.50) MEN1HTTKMT2AHSD17B10LMNA
SCHEMBL4909730 0.71 IGF1R (0.43) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL15722708 0.71 PIK3C3 (0.47) AURKAAURKBPIK3C3RETIGF1R
SCHEMBL18166013 0.70 AURKB (0.66) PLK4AURKAAURKBGSK3BSRC
SCHEMBL219046 0.67 PAK4 (0.59) MEN1HTTKMT2AHSD17B10PLK4
SCHEMBL22600946 0.67 PAK4 (0.59) MEN1HTTKMT2AHSD17B10PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752612-B2 PLK4 inhibitors LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2020-08-25 US disclosed
US-20180086739-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2018-03-29 US disclosed
US-20180086739-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2018-03-29 US disclosed
WO-2016166604-A1 PLK4 INHIBITORS LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086739-A1 PLK4 INHIBITORS PLK4, PLK2, PLK3 MEN1 3811/4885HTT 3287/4885KMT2A 1312/4885
US-10752612-B2 PLK4 inhibitors PLK4, PLK2, PLK3 MEN1 3811/4885HTT 3287/4885KMT2A 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.